Los Angeles, CA 2080 Century Park East Suite 710 Los Angeles, CA 90067





Office: 310-481-9944 Fax: 310-766-7001

Iron (Feraheme/Injectafer/Venofer) Date: Date:			
	•	FORMATION	
Name:		DOB:	
Allergies:		Date of Referral: .	
ICD-10 code (required):	ICD -10 c	lescription:	
□ NKDA Allergies:		Weight lbs/kg:	
Patient Status: ☐ New to Therapy ☐ C REFERRAL STATUS: ☐ New Prescript	ontinuing Therapy Next Due ion □ Order Renewal □Do PROVIDER IN	es or Frequency Change Discontinuation	
Referral Coordinator Name:		oordinator Email:	
Ordering Provider:	Provider N	er NPI:	
Referring Practice Name:	Phone:	Fax:	
Practice Address:	City:	State: Zip Code:	
NURSING □ Provide nursing care per IVX Nursing Procedures, including reaction management and post-procedure observation NOTE: IVX Adverse Reaction Management Protocol available for review at www.ivxhealth.com/forms (version 09.07.2021) PREN-MEDICATION ORDERS		 THERAPY ADMINISTRATION □ Ferumoxytol (Feraheme) intravenous infusion • Dose & Frequency: ☑initial 510mg infusion followed by a second 510mg infusion 3-8 days later • Dilutén 50 - 200ml 0.9% sodium chloride or 5% dextrose solution (final concentration 2mg - 8mg per ml) • Infuse over at least 15 minutes • No refills □ Other 	
□ acetaminophen (Tylenol) □500mg / □ cetirizine (Zyrtec) 10mg PO □ loratadine (Claritin) 10mg PO □ diphenhydramine (Benadryl) □ 25mg □ methylprednisolone (Solu-Medrol) □ □ Other: □ Dose: □ Route: □	g / □50mg □PO / □IV l40mg / □125mg IV	 □ Ferriccarboxymaltose (Injectafer) intravenous infusion ■ Dose & Frequency:□Patients > 50kg: Two 750mg doses, 7 days apart / □Patients < 50kg: Two 15mg/kg doses, 7 days apart ■ Diluten no more than 250ml 0.9% sodium chloride ■ Infuse over at least 15 minutes ■ No refills □ Other □ Iron sucrose(Venofer) intravenous infusion ■ Dose: 	
SPECIAL INSTRUCTIONS		 □ 100mg in 100ml 0.9% sodium chloride over 30 minutes □ 200mg in100ml 0.9% sodium chloride over 30minutes □ 300mg in 250ml 0.9% sodium chloride over 1.5 hours □ 400mg in 250ml 0.9% sodium chloride over 2.5 hours □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	
*Closely observe patients for signs and symptoms of hypersensitivity including monitoring of blood pressure and pulse during and after Feraheme administration for at least 30 minutes and until clinically stable following completion of each infusion. *Observe for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of each administration.*Monitor patients for signs and symptoms of hypersensitivity during and after Venofer administration for at least 30 minutes and until clinically			
Provider Name (Print) ORDERING PROVIDER	Provider Signature	Date	

 Signature X
 Date

 Provider ______ Phone______ Fax ______